Gilead Sciences Really Needs M&A
October 28, 2015 at 10:05 AM EDT
Gilead Sciences (GILD) delivered another beat and raise, but JPMorgan’s Cory Kasimov and team argue that slowing hepatitis-C sales will “keep focus on M&A.” They explain why: Bloomberg News Gilead reported a solid 3Q that included a top- and bottom-line beat and bump to guidance. However, with HCV sales easing back from the peak (no surprise […]
